GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » DeferredTaxAndRevenue

Notable Labs (Notable Labs) DeferredTaxAndRevenue : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Notable Labs's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

Notable Labs DeferredTaxAndRevenue Historical Data

The historical data trend for Notable Labs's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs DeferredTaxAndRevenue Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
DeferredTaxAndRevenue
- - -

Notable Labs Semi-Annual Data
Dec21 Dec22 Dec23
DeferredTaxAndRevenue - - -

Notable Labs DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Notable Labs's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Notable Labs (Notable Labs) Business Description

Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic.